Racial disparities and survival outcome of patients with locally advanced cervix cancer in the international randomised phase 3 OUTBACK trial (ANZGOG 0902, RTOG 1174, NRG 0274)

被引：0
|
作者：
Lee, Yeh Chen
Castellano, Tara
Myers, Tashanna K. N.
Barnes, Elizabeth H.
Chase, Dana Meredith
McCormick, Colleen
Diamante, Katrina
Shannon, Catherine M.
Huh, Warner King
Lea, Jayanthi Sivasothy
Walker, Joan L.
Small, William, Jr.
Miller, Katherine
Govindarajulu, Geetha
Monk, Bradley J.
Stockler, Martin R.
Moore, Kathleen N.
Mileshkin, Linda R.
Bae-Jump, Victoria Lin
机构：
[1] Univ Sydney, NHMRC Clin Trials Ctr, Sydney, NSW, Australia
[2] Louisiana State Univ, Dept Gynecol Oncol, New Orleans, LA USA
[3] Baystate Med Ctr, Springfield, MA USA
[4] Univ Calif Los Angeles, Dept Obstet & Gynecol, Div Gynecol Oncol, Los Angeles, CA 90024 USA
[5] Univ New Mexico Canc Ctr, Albuquerque, NM USA
[6] Univ Sydney, NHMRC Clin Trials Ctr, Camperdown, NSW, Australia
[7] Mater Canc Care Ctr, South Brisbane, Australia
[8] Univ Alabama Birmingham, Birmingham, AL USA
[9] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA
[10] Univ Oklahoma Hlth Sci Ctr, Oklahoma City, OK USA
[11] Loyola Univ Med Ctr, Maywood, IL 60153 USA
[12] Women & Infants Hosp Rhode Isl, Providence, RI 02908 USA
[13] Calvary Mater Newcastle, Newcastle, NSW, Australia
[14] Univ Arizona Coll Med, HonorHlth Res Inst, Div Gynecol Oncol, Phoenix, AZ USA
[15] Creighton Univ Sch Med, Phoenix, AZ USA
[16] Univ Sydney, Camperdown, NSW, Australia
[17] Oklahoma Univ Hlth, Stephenson Canc Ctr, Oklahoma City, OK USA
[18] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia
[19] Peter MacCallum Canc Ctr, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia
[20] Univ Melbourne, Melbourne, Vic, Australia
[21] Univ North Carolina Chapel Hill, Chapel Hill, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1594
引用
收藏
页数：1
相关论文
共 41 条
  • [31] Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management
    Smith, J. Joshua
    Chow, Oliver S.
    Gollub, Marc J.
    Nash, Garrett M.
    Temple, Larissa K.
    Weiser, Martin R.
    Guillem, Jose G.
    Paty, Philip B.
    Avila, Karin
    Garcia-Aguilar, Julio
    BMC CANCER, 2015, 15
  • [32] Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial
    Kawashima, Yosuke
    Fukuhara, Tatsuro
    Saito, Haruhiro
    Furuya, Naoki
    Watanabe, Kana
    Sugawara, Shunichi
    Iwasawa, Shunichiro
    Tsunezuka, Yoshio
    Yamaguchi, Ou
    Okada, Morihito
    Yoshimori, Kozo
    Nakachi, Ichiro
    Seike, Masahiro
    Azuma, Koichi
    Kurimoto, Futoshi
    Tsubata, Yukari
    Fujita, Yuka
    Nagashima, Hiromi
    Asai, Gyo
    Watanabe, Satoshi
    Miyazaki, Masaki
    Hagiwara, Koichi
    Nukiwa, Toshihiro
    Morita, Satoshi
    Kobayashi, Kunihiko
    Maemondo, Makoto
    LANCET RESPIRATORY MEDICINE, 2022, 10 (01): : 72 - 82
  • [33] InterAACT: A multicentre open label randomised phase II advanced anal cancer trial of cisplatin (CDDP) plus 5-fluorouracil (5-FU) vs carboplatin (C) plus weekly paclitaxel (P) in patients (pts) with inoperable locally recurrent (ILR) or metastatic treatment naive disease - An International Rare Cancers Initiative (IRCI) trial
    Rao, S.
    Sclafani, F.
    Eng, C.
    Guren, M. Gronlie
    Adams, R. A.
    Benson, A.
    Sebag-Montefiore, D.
    Segelov, E.
    Bryant, A.
    Peckitt, C.
    Roy, A.
    Seymour, M. T.
    Welch, J.
    Saunders, M. P.
    Muirhead, R.
    Bridgewater, J.
    Falk, S.
    Glynne-Jones, R.
    Arnold, D.
    Cunningham, D.
    ANNALS OF ONCOLOGY, 2018, 29
  • [34] Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial
    Thomalla, Goetz
    Bonekamp, Susanne
    Fiehler, Jens
    Bendszus, Martin
    LANCET, 2024, 404 (10464): : 1730 - 1730
  • [35] Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed high-risk, locally advanced cervical cancer (ENGOT-cx11/ GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial
    Lorusso, Domenica
    Xiang, Yang
    Hasegawa, Kosei
    Scambia, Giovanni
    Leiva, Manuel
    Ramos-Elias, Pier
    Acevedo, Alejandro
    Cvek, Jakub
    Randall, Leslie
    Gomes, Andrea Juliana Pereira de Santana
    Mejia, Fernando Contreras
    Helpman, Limor
    Akilli, Huseyin
    Lee, Jung-Yun
    Saevets, Valeriya
    Zagouri, Flora
    Gilbert, Lucy
    Sehouli, Jalid
    Tharavichitkul, Ekkasit
    Lindemann, Kristina
    Colombo, Nicoletta
    Chang, Chih-Long
    Bednarikova, Marketa
    Zhu, Hong
    Oaknin, Ana
    Christiaens, Melissa
    Petru, Edgar
    Usami, Tomoka
    Liu, Peng
    Yamada, Karin
    Toker, Sarper
    Keefe, Stephen M.
    Pignata, Sandro
    Duska, Linda R.
    LANCET, 2024, 404 (10460): : 1321 - 1332
  • [36] Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial (vol 14, pg 989, 2013)
    Johnston, S. R. D.
    Kilburn, L. S.
    Ellis, P.
    LANCET ONCOLOGY, 2013, 14 (10): : E391 - E391
  • [37] A multicentre, international, randomised, open-label phase 3 trial of avelumab plus best supportive care (BSC) vs BSC alone as maintenance therapy after first-line platinum-based chemotherapy in patients with advanced urothelial cancer (JAVELIN bladder 100)
    Powles, T.
    Grivas, P.
    Aragon-Ching, J. B.
    Faroun, Y.
    Kessler, E. R.
    Tomita, Y.
    Chakrabarti, D.
    Laliberte, R. J.
    Shnaidman, M.
    Petrylak, D.
    ANNALS OF ONCOLOGY, 2016, 27
  • [38] Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial (vol 18, pg 732, 2017)
    Dieras, V
    Miles, D.
    Verma, S.
    LANCET ONCOLOGY, 2018, 19 (12): : E667 - E667
  • [39] Entinostat, a class I selective histone deacetylase inhibitor, plus exemestane for Chinese patients with hormone receptor-positive advanced breast cancer: An overall survival update and long-term safety from the randomised, double-blind, placebo-controlled, phase 3 trial
    Wang, Jiani
    Zhang, Qingyuan
    Hu, Xichun
    Li, Qing
    Sun, Tao
    Li, Wei
    Ouyang, Quchang
    Wang, Jingfen
    Tong, Zhongsheng
    Yan, Min
    Li, Huiping
    Zeng, Xiaohua
    Shan, Changping
    Wang, Xian
    Zhang, Jian
    Zhang, Yue
    Zhang, Liang
    Tian, Ying
    Shang, Hongyan
    Xu, Binghe
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [40] Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial (vol 18, pg 732, 2017)
    Dieras, V
    Miles, D.
    Verma, S.
    LANCET ONCOLOGY, 2017, 18 (08): : E433 - E433
12345